X4 Pharmaceuticals (XFOR)
Commercializing XOLREMDI while advancing mavorixafor for chronic neutropenia.
Something off on this page? Send us feedback.
XOLREMDI sales in the United States and a Norgine licensing agreement provide revenue around a single CXCR4 medicine. Mavorixafor's pivotal chronic-neutropenia study is the company's main expansion path.
Commercializes XOLREMDI, an oral CXCR4 antagonist approved in the United States for WHIM syndrome. The medicine is designed to mobilize neutrophils and lymphocytes from bone marrow into peripheral circulation. The same molecule, mavorixafor, is in the global pivotal 4WARD study for chronic neutropenia, leaving the business with one marketed medicine and one main expansion program.
U.S. XOLREMDI sales are its product-revenue source, alongside licensing revenue from a Norgine agreement. Following its restructuring, operations are concentrated on commercializing XOLREMDI and completing 4WARD, with clinical and manufacturing partners and continued access to capital shaping execution.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jul 10, 2026 | Wells Fargo | Initiate | Overweight | $11 | |
| Jun 2, 2026 | Leerink Partners | Target | $12 | ||
| Mar 9, 2026 | Guggenheim | Target | $12 | ||
| Dec 5, 2025 | Stifel Nicolaus | Target | $7.50 | $10 | |
| Nov 5, 2025 | Stifel Nicolaus | Target | $9 | $7.50 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $208.0M · Total debt $77.2M · Total assets $253.1M · Shareholders' equity $155.5M
- Revenue
- $8.8M
- Operating income
- −$16.4M
- Net income
- −$16.2M
No dividends on record.
| Institutions81 holders · as of Mar 31, 2026 | 91.22% | 90.44M shares | |
| Insiders15 holders · as of Aug 13, 2026 | 0.95% | 938.2K shares | |
| Otherremainder | 7.83% | 7.77M shares |
99.15M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Morgan StanleyInstitution | 9.55% | 9.47M | 13Fas of Mar 31, 2026 |
Empery Asset Management, LPInstitution | 9.02% | 8.94M | 13Fas of Mar 31, 2026 |
FMR LLCInstitution | 8.17% | 8.10M | 13Fas of Mar 31, 2026 |
Bain Capital Life Sciences Investors, LLCInstitution | 8.04% | 7.97M | 13Fas of Mar 31, 2026 |
Perceptive Advisors LLCInstitution | 6.80% | 6.74M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 12, 2026 | John Volpone | officer: President | −24,576 | $4.44 |
| Aug 12, 2026 | Adam R. Craig | director, officer: Executive Chairman | −47,436 | $4.44 |
| Jun 30, 2026 | David Kirske | officer: Chief Financial Officer | −8,543 | $4.26 |
| May 12, 2026 | David Kirske | officer: Chief Financial Officer | −16,961 | $4.29 |
| Oct 23, 2025 | Adam R. Craig | director, officer: Executive Chairman | +86,206 | $2.90 |
- Amgen
Reference G-CSF therapy in chronic neutropenia
- Pfizer
Filgrastim biosimilar option in chronic neutropenia
- Amneal Pharmaceuticals
Filgrastim biosimilar option in chronic neutropenia
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| X4 Pharmaceuticals | $4.01 | −0.87% | $381.1M | — | — | 24.0 | +346.3% |
| Amgen | $443.00 | +0.04% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Pfizer | $28.98 | −0.17% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Amneal Pharmaceuticals | $18.01 | −0.33% | $5.77B | 37.0 | 18.1 | 1.8 | +9.9% |
| Median | 37.0 | 18.1 | 2.6 | +9.7% |